Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Net revenue for the first half of 2022 increased 45.5% period-over-period to $42.8 million Positive results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell... | August 11, 2022

Related Keywords

Miami ,Florida ,United States ,Japan ,San Francisco ,California ,Japanese ,American ,Mazyar Shadman ,Fred Hutch ,Jaclyn Jaffe ,Caelum Biosciences ,Lindsaya Rosenwald ,Tony Plohoros ,David Jin ,National Institute Of Allergy ,American Society Of Gene Cell Therapy ,Nasdaq ,International Blood Marrow Transplant Research ,American Society Of Clinical Oncology Annual Meeting ,American Association For Cancer Research Annual Meeting ,Astrazeneca ,International Workshop ,Fred Hutchinson Cancer Research Center ,American Society Of Transplantation ,Checkpoint Therapeutics Inc ,National Institutes Of Health ,Drug Administration ,Journey Medical Corporation ,Sentynl Therapeutics Inc ,Regulatory Agency ,Head Of Corporate Development ,Exchange Commission ,Securities Exchange ,Fortress Biotech Inc ,Cyprium Therapeutics Inc ,European Hematology Association ,Research Hospital ,Caelum Biosciences Inc ,Company Quarterly Report On Form ,Globenewswire Inc ,Master Services Agreement ,Company Contacts ,Mustang Bio Inc ,Avenue Therapeutics Inc ,European Medicines Agency ,Fortres Chairman ,Chief Executive Officer ,Biologics License Application ,Cyprium Therapeutics ,Drug Application ,Dermatology Products ,Medical Corporation ,Journey Medical ,Light Chain Fibril Reactive Monoclonal Antibody ,Pediatric Investigation Plan ,Medicines Agency ,Clinical Oncology Annual ,Copper Histidinate ,Quarterly Report ,Cell Therapy ,Meetingsi Transplantation ,Cellular Therapy Meetings ,Cellular Therapy ,International Blood ,Marrow Transplant ,Hematology Association ,Orphan Drug Designation ,Lentiviral Gene Therapies ,Mustang Bio ,Clinical Trials Spotlight Symposium ,Jude Children ,Seattle Children ,Investigational New Product Drug Application ,Infectious Diseases ,Urate Transporter ,Lentiviral Gene Therapy ,Combined Immunodeficiency ,Nationwide Children ,Cancer Research Annual Meeting ,Corporate Development ,Chief Financial Officer ,Avenue Therapeutics ,Hutchinson Cancer Research Center ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Relations Contact ,Condensed Consolidated Statements ,Fortress Biotech ,Nc Stock Exchange ,News ,Information ,Press Release ,Pet ,Revenue ,Or ,The ,First ,Calf ,F ,022 ,Ncreased ,O ,Billion ,Positive ,Results ,Rom ,Study ,Cosibelimab ,N ,Metastatic ,Cutaneous ,Quamous Fbio Us34960q1094 ,